MIRANSERTIB

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C27H24N6
Molecular Weight	432.5197
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=NC=CC=C1C2=NC3=CC=C(N=C3N2C4=CC=C(C=C4)C5(N)CCC5)C6=CC=CC=C6

InChI

InChIKey=HNFMVVHMKGFCMB-UHFFFAOYSA-N

InChI=1S/C27H24N6/c28-24-21(8-4-17-30-24)25-32-23-14-13-22(18-6-2-1-3-7-18)31-26(23)33(25)20-11-9-19(10-12-20)27(29)15-5-16-27/h1-4,6-14,17H,5,15-16,29H2,(H2,28,30)

HIDE SMILES / InChI

Molecular Formula	C27H24N6
Molecular Weight	432.5197
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.arqule.com/pipeline/arq-092/ | https://clinicaltrials.gov/ct2/show/NCT03094832 | https://www.ncbi.nlm.nih.gov/pubmed/30399177

Miransertib (ARQ 092) is a selective, pan-AKT (protein kinase B) inhibitor that potently inhibits AKT1, 2 and 3 isoforms. Miransertib binds inactive AKT, preventing membrane localization and subsequent AKT activation, and binds active AKT, resulting in direct inhibition. Miransertib participates in Phase 1/2 of clinical trials to treat patients at least 2 years of age with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS). In addition, the drug is involved in the phase I trial in patients with lymphoma, endometrial cancer, and AKT1 E17K mutations. Recently was shown that miransertib could be an excellent lead compound for the development of new oral drug therapy for visceral and cutaneous leishmaniasis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Serine/threonine-protein kinase AKT 31 Target ID: CHEMBL4282 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27305487	Inhibitor 8504	2.7 nM [IC50]
Serine/threonine-protein kinase AKT2 17 Target ID: CHEMBL2431 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27305487	Inhibitor 8504	14.0 nM [IC50]
Serine/threonine-protein kinase AKT3 17 Target ID: CHEMBL4816 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27305487	Inhibitor 8504	8.1 nM [IC50]

C_max

Value	Dose	Co-administered	Analyte	Population
1167 nM EXPERIMENT https://pdfs.semanticscholar.org/942c/bcd607c5bd04ed1c9b7af054464aa0cf452e.pdf	200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		MIRANSERTIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
20624 nM × h EXPERIMENT https://pdfs.semanticscholar.org/942c/bcd607c5bd04ed1c9b7af054464aa0cf452e.pdf	200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		MIRANSERTIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
36 h EXPERIMENT https://pdfs.semanticscholar.org/942c/bcd607c5bd04ed1c9b7af054464aa0cf452e.pdf	200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		MIRANSERTIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

PubMed

Title	Date	PubMed
Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma.	2018-02-16	29541403
ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease.	2017-02	27758820

Sample Use Guides

In Vivo Use Guide

ARQ 092 orally at 15 mg/m2 QD for the first 3 cycles on a 28 day schedule

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:01:28 GMT 2025` Edited by `admin` on `Mon Mar 31 21:01:28 GMT 2025`
Record UNII	T1DQI1B52Y
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

miransertib [INN]

Preferred Name

English

MIRANSERTIB

Official Name

English

ARQ-092

Code

English

Miransertib [WHO-DD]

Common Name

English

2-PYRIDINAMINE, 3-(3-(4-(1-AMINOCYCLOBUTYL)PHENYL)-5-PHENYL-3H-IMIDAZO(4,5-B)PYRIDIN-2-YL)-

Systematic Name

English

3-(3-(4-(1-AMINOCYCLOBUTYL)PHENYL)-5-PHENYL-3H-IMIDAZO(4,5-B)PYRIDIN-2-YL)-2-PYRIDINAMINE

Systematic Name

English

ARQ092

Code

English

MIRANSERTIB [USAN]

Common Name

English

3-(3-(4-(1-AMINOCYCLOBUTYL)PHENYL)-5-PHENYL-3HIMIDAZO(4,5-B)PYRIDIN-2-YL)PYRIDIN-2-AMINE

Systematic Name

English

ARQ092 FREE BASE

Code

English

Classification Tree Code System Code

FDA ORPHAN DRUG

497115